Details of the Drug Combination

General Information of Drug Combination (ID: DCATITY)

Drug Combination Name
ARRY-162 Lorlatinib
Indication
Disease Entry Status REF
Lung Cancer Phase 1 [1]
Component Drugs ARRY-162   DM1P6FR Lorlatinib   DMICDLV
Small molecular drug N.A.
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of ARRY-162
Disease Entry ICD 11 Status REF
Melanoma 2C30 Approved [2]
ARRY-162 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
MAPK/ERK kinase kinase (MAP3K) TTROQ37 NOUNIPROTAC Modulator [3]
ERK activator kinase (MEK) TTZCRP3 NOUNIPROTAC Inhibitor [2]
------------------------------------------------------------------------------------
ARRY-162 Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [4]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [4]
------------------------------------------------------------------------------------
ARRY-162 Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [5]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
Indication(s) of Lorlatinib
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Approved [2]
Lorlatinib Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
ALK tyrosine kinase receptor (ALK) TTPMQSO ALK_HUMAN Inhibitor [2]
Proto-oncogene c-Ros (ROS1) TTSZ6Y3 ROS1_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
Lorlatinib Interacts with 7 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [7]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [8]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [7]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [7]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Metabolism [7]
UDP-glucuronosyltransferase 1A4 (UGT1A4) DELOY3P UD14_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DME(s)

References

1 ClinicalTrials.gov (NCT04292119) Lorlatinib Combinations in Lung Cancer
2 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
3 MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27.
4 The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors. Int J Cancer. 2018 Jan 15;142(2):381-391.
5 FDA Label of Binimetinib. The 2020 official website of the U.S. Food and Drug Administration.
6 Binimetinib - European Medicines Agency - European Union
7 FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
8 Product characteristics of Lorviqua.